EBITDA grew 26 per cent at Rs 123 crore
Ajanta Pharma has reported today its performance for the first quarter ended June 30, 2015. Consolidated revenue from operations grew 77 per cent at Rs 391 crore against Rs 322 crore. EBITDA grew 26 per cent at Rs 123 crore against Rs 97 crore and EBITDA was at 31 per cent of revenue. Profit before tax grew 35 per cent at Rs 118 crore against Rs 87 crore. Profit after tax grew 41 per cent at Rs 84 crore against Rs 60 crore, PAT was at 21 per cent of revenue.
The company’s standalone revenue from operations grew 18 per cent at Rs 341 crore against Rs 287 crore. EBITDA grew 22 per cent was at Rs 110 crore against Rs 90 crore. EBITDA was at 32 per cent of revenue. Profit before tax grew 33 per cent at Rs 113 crore against Rs 85 crore. Profit after tax grew 38 per cent at Rs 81 crore against Rs 59 crore, PAT at 24 per cent of revenue.
For Q1 FY2016, the overall lndia business was Rs 144 crore, up 21 per cent over Q1 FY2015. Out of this, lndian branded business was Rs 128 crore. posting a healthy growth of 18 per cent as against the industry growth of 14 per cent. Institution sales was Rs 16 crore, posting a growth of 58 per cent over previous year quarter. During the quarter, seven new products were launched, out-of-which two were first to market.
Yogesh M Agrawal, Managing Director, Ajanta Pharma said, “We have delivered another quarter of competitive growth and margin improvement ahead of the market. Our strategy remains focused on strengthening the core of our business which is refining the thrust on brand building, increasing the intensity on R&D and continuous improvement of our executional capabilities. We intend to enhance our focus on R&D in coming year to augment our capabilities which will be essential to deliver sustained growth.”
Comments are closed.